Intravitreal Bevacizumab (Avastin) for neovascular age-related macular degeneration - ND

• Conditions: Viasual acuity loss; MedDRA version: 9.1Level: SOCClassification code 10015919Term: Eye disorders

• Registration Number: EUCTR2006-004320-36-IT
• Lead Sponsor: AZIENDA OSPEDALIERA SENESE

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-05-03
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

- neovascular age-related macular degeneration

- age > 55

- Visual loss <4/10
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- previous ocular infections

- intravitreal hemoragies

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: Viasual acuity loss prevention in patients with age-related macular degeneration vs standard therapy;Secondary Objective: - Improvement in visual acuity, OCT and angiographic outcomes;Primary end point(s): Viasual acuity loss prevention in patients with age-related macular degeneration vs standard therapy